CD274 and urothelial carcinoma: PD-1/PD-L1 inhibitors have been approved for many solid tumors and hematological malignancies, including non-small cell lung cancer, melanoma, urothelial carcinoma, esophageal carcinoma, renal cell carcinoma, and Hodgkin’s lymphoma (32).